Dexcom G7 is our most accessible and affordable glucose sensor ever, covered by most private insurers and many provincial health programs, making it easier for individuals on insulin to proactively...

A recent clinical study 1 found encouraging accuracy results for pregnant women who used the Dexcom G7 real-time Continuous Glucose Monitoring (rtCGM) System . The study followed 96 pregnant women...

The 2023 Preechasuk study of adults with type 1 diabetes (T1D) who switched from an intermittently scanned continuous glucose monitoring (isCGM) device to Dexcom G7 real-time Continuous Glucose Monitoring (rtCGM)...

Dexcom real-time Continuous Glucose Monitoring (rtCGM) systems can be quickly and easily prescribed through most electronic medical record (EMR) systems used in Canada. This allows healthcare providers to streamline their...

The COMISAIR 7-year study is the longest prospective real-world rtCGM study ever conducted. Preliminary results presented at EASD show using a real-time continuous glucose monitoring system (rtCGM), like Dexcom G7...

The American Diabetes Association recently published the 2024 Standards of Care guidelines, recommending real-time continuous glucose monitoring (rtCGM) as a standard of care for people living with diabetes—including pregnant women...